Pharmaceutical Technology

MARCH 4, 2023

Treprostinil SR is under clinical development by Camurus and currently in Phase II for Raynauds Disease. It sells drugs under the brand name of Episil, FluidCrystal. The company has developmental and commercial collaborations with biotechnology and pharmaceutical companies for product development.

Drugs 100

Drugs Development Clinical Trials Clinical Trials 100

Pharmaceutical Technology

MARCH 4, 2023

Treprostinil SR is under clinical development by Camurus and currently in Phase II for Raynauds Disease. It sells drugs under the brand name of Episil, FluidCrystal. The company has developmental and commercial collaborations with biotechnology and pharmaceutical companies for product development.

Drugs 100

Drugs Development Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 27, 2023

Hydrocortisone is under clinical development by Antares Pharma and currently in Phase I for Adrenal Insufficiency. It also develops products to reduce the risk of preterm birth in pregnant women. It caters its subcutaneous injection technology platforms to both generic and branded injectables.

Drug Delivery 100

Drug Delivery Drug Delivery Systems Production Drugs 100

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). It markets its consumer products under various brands which include 3M Futuro, Altrix Range, Avene, Bio Oil, Puria and Resolve, among others.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). It markets its consumer products under various brands which include 3M Futuro, Altrix Range, Avene, Bio Oil, Puria and Resolve, among others.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

JULY 26, 2022

There are two branded miglustat therapies available across the 3MM, with the US market having Johnson and Johnson’s (J&J, US) Zavesca and also generic miglustat available, but neither of these are approved for the treatment of NPC, so physicians prescribe this therapy off-label.

Marketing 306

Marketing Gene Branding Sales 306

Intouch Solutions

FEBRUARY 23, 2023

A 2021 Accenture survey of 12,000 patients in six countries found that only 16% were aware of a patient service offered to them by a brand. DTC ads and patient creative may need to elevate a brand’s financial offerings. Agile brands are recutting existing TV spots to include information about copay cards or financial assistance.

Marketing 52

Marketing Branding Life Science Clinical Trials 52

Intouch Solutions

FEBRUARY 23, 2023

A 2021 Accenture survey of 12,000 patients in six countries found that only 16% were aware of a patient service offered to them by a brand. DTC ads and patient creative may need to elevate a brand’s financial offerings. Agile brands are recutting existing TV spots to include information about copay cards or financial assistance.

Marketing 52

Marketing Branding Life Science Clinical Trials 52

Drug Discovery World

AUGUST 30, 2022

The importance of brand stratefy & development in your commercialisation journey. Patient engagement during clinical development: keeping the “customer” in mind. The roundtables include: 1. Operational excellence within manufacturing: Commercalisation vs cost.

Gene Therapy 98

Gene Therapy Gene Clinical Trials Clinical Trials 98

pharmaphorum

MARCH 15, 2022

It’s an example of a fairly uncommon risk-sharing model, in which an investment group funds a clinical development programme in the hope of a bigger payoff down the line, with rights to the drug staying with the pharma partner. Sarclisa has been tipped to become a $1 billion-plus brand, but it still has a long way to go.

Trials 97

Trials Sales Drug Delivery Antibody 97

XTalks

JANUARY 6, 2021

Some include Mind Medicine, Compass Pathways and Champignon Brands. Due to the team’s experience, we have an extensive playbook to draw from to manage clinical trials even under the most trying of times.” Champignon Brands. Mind Medicine.

Drugs 97

Drugs Clinical Trials Clinical Trials Medicine 97

Cloudbyz

MAY 4, 2022

Through innovative digital clinical research solutions and services, Cloudbyz, a fast-growing clinical research and development solution provider with integrated capabilities helps life sciences organizations to bring new therapies and medical devices faster to market reliably.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

pharmaphorum

JANUARY 19, 2022

From clinical development to commercialization, cross?functional Fishawack Health has had the privilege of working on dozens of new drug launches in recent years as the Brand Agency of Record—working with many biotech and biopharma companies on their first commercial launch. tracked or receives priority review.

Production 52

Production Branding Sales Clinical Development 52

pharmaphorum

OCTOBER 27, 2021

With over 50 speakers each sharing brand new sessions, the main focus?areas areas for 2022 include: Understanding the Pre- Clinical & Clinical Developments of Microbiome-based Therapeutics – INCLUDING a Range of Disease-Specific Case Studies. Download the full event guide for the speaker faculty and session details.

Development 52

Development Drugs Manufacturing Branding 52

pharmaphorum

SEPTEMBER 17, 2020

The UK big pharma hasn’t revealed how much it is paying for rights to the drug candidate, originally developed by US biotech Dogma Therapeutics, which is still in preclinical development. At the moment no oral PCSK9 drugs have started clinical development, and AZ says it intends to start clinical testing of Dogma’s candidate next year.

Drugs 61

Drugs Antibody Sales Branding 61

The Pharma Data

MARCH 23, 2023

The new Phase III clinical study, ARASTEP, will investigate the efficacy of darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline.

Hormones 40

Hormones Trials Branding Development 40

pharmaphorum

JANUARY 28, 2022

Biogen will retain its commercial rights to the biosimilars already brought to market, as well as copycat version of Bayer’s age-related macular degeneration blockbuster Eylea (aflibercept) that is still in clinical development.

Sales 52

Sales Marketing Branding Production 52

pharmaphorum

SEPTEMBER 20, 2021

However, Byooviz – which also has mCNV and RVO on its US label – isn’t due to launch there until next year under the terms of a deal with Roche, which has US rights to the Lucentis brand and claims additional patent protection until 2022.

Drugs 70

Drugs Sales FDA Approval Marketing 70

pharmaphorum

NOVEMBER 9, 2022

The financing is also joined by additional new investor Brandon Capital and founding investor Parkinson’s Virtual Biotech, which is the international drug discovery and development programme begun in 2017 by Parkinson’s UK. It has been supporting NRG’s work since 2019.

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

pharmaphorum

APRIL 28, 2022

But the company was inspired to re-brand its rare disease business unit as a response to internal ramp-ups that have occurred over the last few years, Helfgott said. The new hub will focus on centralising things like clinical development strategy, clinical operations, and regulatory approval strategy – not necessarily drug development itself.

Pharma Companies 57

Pharma Companies Branding Development Marketing 57

XTalks

JUNE 14, 2023

The exact cost of Vevye has not been publicly disclosed; however, it is estimated that the price of Vevye may be in the range of similar cyclosporine ophthalmic emulsions, such as brand-name Restasis that carries a list price of $645.63 One such approved medication is Miebo , an ophthalmic solution developed by Bausch + Lomb and Novaliq.

Gene Silencing 97

Gene Silencing Drug Delivery FDA Approval RNA 97

pharmaphorum

SEPTEMBER 21, 2021

As these promising therapies move into clinical development, we need to ensure qualified patients are diagnosed, identified and engaged early on in drug development and aware of these trials so that these innovations have the best possible chance to make it to patients.

Gene Therapy 88

Gene Therapy Gene Clinical Trials Clinical Trials 88

The Pharma Data

FEBRUARY 21, 2022

Elinzanetant, a non-hormonal development compound, is currently being investigated in the Phase III clinical development program OASIS for the treatment of vasomotor symptoms during menopause. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. billion euros.

Radiology 52

Radiology Cardiology Development Production 52

The Pharma Data

FEBRUARY 13, 2022

About Asundexian and FXIa Inhibitors Asundexian (BAY2433334) is an oral Factor XIa (FXIa) inhibitor (anti-thrombotic) and is part of a portfolio of assets targeting FXI or FXIa inhibitors currently in clinical development by Bayer. Bayer is committed to drive sustainable development and generate a positive impact with its businesses.

Clinical Trials 40

Clinical Trials Clinical Trials Life Science Trials 40

The Pharma Data

JUNE 28, 2021

Bayer announced today that the Ministry of Health, Labour, and Welfare (MHLW) in Japan has approved soluble guanylate cyclase (sGC) stimulator vericiguat under the brand name Verquvo. Heart failure affects approximately 1.2 million people in Japan. Verquvo (vericiguat) 2.5

Cardiology 52

Cardiology Production Development Medicine 52

The Pharma Data

APRIL 4, 2022

The extensive Actemra/RoActemra RA intravenous (IV) clinical development programme included five phase III clinical studies and enrolled more than 4,000 people with RA in 41 countries.

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials In-Vitro 52

The Pharma Data

NOVEMBER 18, 2020

Kai-Uwe Schässburger Director Clinical Development & Medical Affairs +49 (0)151 688 092 41 or + 46 (0)762 386 153 e-mail: kai-uwe.schassburger@neodynamics.com. NeoNavia is evaluated at leading clinics in UK, Germany and Sweden. About NeoNavia.

Branding 52

Branding Clinical Development Marketing Regulation 52

The Pharma Data

OCTOBER 19, 2020

She is executive medical director of immunology clinical development for the pharmaceutical company AbbVie in North Chicago, Ill. The drug, marketed under the brand name Rinvoq, also helped twice as many patients enter remission from their rheumatoid arthritis, according to a report in the Oct. ” Rinvoq received U.S.

Drugs 52

Drugs Clinical Trials Clinical Trials Trials 52

XTalks

MAY 31, 2023

As the world’s largest pure-play consumer health company in terms of revenue, Kenvue is renowned for its portfolio of iconic brands, including Aveeno, BAND-AID Brand Adhesive Bandages, Johnson’s, Listerine, Neutrogena, Tylenol and Zyrtec. This therapy holds promise in the field of cancer treatment.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Production 97

The Pharma Data

DECEMBER 23, 2020

The Company has Now Resumed the Clinical Development of its Proposed Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum. With this funding now complete, the Company is excited about its prospects for 2021 – as it pertains to its pharmaceutical development efforts. . NEW YORK, NY, Dec.

Life Science 52

Life Science Manufacturing Production Development 52

Delveinsight

FEBRUARY 5, 2021

Whenever the branded drugs go off-the-market, it paves the way for the entry of generics in the market. Generic medications are the same as the original branded ones, but cheaper. Moreover, the generic drugs of Zyban are also approved, while for Chantix, its patent is soon going to expire in 2021 in the EU and in 2022 in Japan.

Marketing 52

Marketing FDA Approval Branding Production 52

The Pharma Data

DECEMBER 13, 2020

Zai Labs obtained regional development and commercialization rights for the programs in mainland China, Hong Kong, Macau and Taiwan. Zai Lab is leading clinical development in its territory. “We Amgen has a target action date of December 19 for its BLA for ABP 798, a biosimilar to Genentech’s Rituxan (rituximab).

Antibody 52

Antibody Clinical Trials Clinical Trials Licensing 52

The Pharma Data

MAY 31, 2022

Senior Vice President, Clinical Development, BlueRock Therapeutics. “We We are excited that our Phase 1 clinical trial has completed enrollment and believe it is a critical next step toward the development of a novel cell therapy that has the potential to transform the treatment landscape for this devastating disease.”.

Trials 52

Trials Engineer Clinical Trials Clinical Trials 52

The Pharma Data

MARCH 23, 2021

Berlin, March 23, 2021 – Bayer announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for larotrectinib, under the brand name Vitrakvi , for the treatment of Neurotrophic Tyrosine Receptor Kinase ( NTRK ) fusion-positive advanced or recurrent solid tumors. About Oncology at Bayer.

Genome 52

Genome Genomics Gene Protein 52

The Pharma Data

DECEMBER 28, 2020

Novotech Health Holdings (“Novotech Holdings”) is the leading Asian biotech CRO and consists of two operating brands, Novotech and PPC. Novotech Holdings is a full-service CRO with integrated labs and phase I facilities providing drug development consulting and clinical development services.

Clinical Trials 40

Clinical Trials Clinical Trials Research Analyst Trials 40

The Pharma Data

DECEMBER 17, 2020

Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group.

Development 52

Development Gene Therapy Engineer Life Science 52

Delveinsight

AUGUST 17, 2020

million in 2019 and is anticipated to increase at a CAGR for the study period 2017-2030 owing to dynamic pipeline therapies in the mid-/ late-stage clinical development and rising gastroparesis prevalence. The Gastroparesis market size in the 7MM was found to be USD 3,170.01

Marketing 54

Marketing FDA Approval Trials Clinical Development 54